Changeflow GovPing Pharma & Drug Safety Conjugates for Cancer Treatment - Patent Applic...
Routine Notice Added Final

Conjugates for Cancer Treatment - Patent Application US20260097117A1

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO published patent application US20260097117A1 for conjugates comprising a binding moiety and an immunomodulatory imide compound, such as substituted isoindoline compounds, useful for treating cancer. The application was filed October 2, 2025, by inventors Nathan Fishkin and Peter U. Park, with a publication date of April 9, 2026.

What changed

USPTO published patent application US20260097117A1 disclosing conjugates comprising a binding moiety and an immunomodulatory imide compound, such as substituted isoindoline compounds, conjugated via an optional linker. The disclosed conjugates and compositions are intended for treating diseases including cancer. The application covers compositions and methods useful in cancer treatment applications.\n\nAffected parties including pharmaceutical companies, biotechnology researchers, and developers of immunomodulatory therapies should monitor this patent prosecution for potential implications on the IP landscape for cancer treatment conjugates. Competitors developing similar immunomodulatory conjugate technologies should assess freedom-to-operate implications.

What to do next

  1. Monitor for patent prosecution updates
  2. Review for freedom-to-operate considerations

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CONJUGATES

Application US20260097117A1 Kind: A1 Apr 09, 2026

Inventors

Nathan FISHKIN, Peter U. PARK

Abstract

The present disclosure provides conjugates comprising a binding moiety and an immunomodulatory imide compound, e.g., substituted isoindoline compound, wherein the immunomodulatory imide compound is conjugated to a binding moiety via an optional linker. Also provided are compositions comprising the conjugates. The conjugates and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

CPC Classifications

A61K 39/39 A61K 39/0011 A61K 47/6803 A61K 47/6849 A61K 47/6855 A61K 47/6889 C07D 409/14

Filing Date

2025-10-02

Application No.

19348414

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097117A1

Who this affects

Applies to
Pharmaceutical companies Research institutions
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Cancer treatment research Immunomodulatory compound development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!